This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the transfer time, which can be streamlined by pathology reflex testing. Delays in TAT affect the timing ...
In this interview, Vernon Sondak, MD, the chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Florida, explains the latest approach to treating ...
The US Food and Drug Administration has granted accelerated approval to dabrafenib (Tafinlar) plus trametinib (Mekinist) for adult and pediatric patients aged 6 years and older with unresectable or ...
Martin Dietrich, MD, PhD, of Florida Cancer Specialists spoke with The American Journal of Managed Care® (AJMC®) on risk factors in melanoma, as well as the need for genomic testing and rapid action ...
image: Joan Seoane, Co-Director of Preclinical and Translational Research at the Vall d’Hebron Institute of Oncology (VHIO). view more Published in Cancer Research, findings reveal the potent and ...
BRAFTOVI + MEKTOVI continued to show substantial antitumor activity after a minimum follow up of approximately three years, corresponding to the longest duration of response and progression-free ...
A Marathon Not a Sprint: Improving Outcomes for Patients With Metastatic Melanoma in 2022 and Beyond This study showed variations in BRAF test results in TAT. One factor affecting this timeline is the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results